Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 34, 2023 - Issue 1
Submit an article Journal homepage
1,234
Views
1
CrossRef citations to date
0
Altmetric
Letter to the Editor

Real-life effectiveness and safety of dupilumab in adolescents with atopic dermatitis: a 52-week single-center retrospective study

Luigi Gargiuloa Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, MI, Italy;b Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, ItalyView further author information
,
Carlo Alberto Vignolia Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, MI, Italy;b Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-0452-8710View further author information
ORCID Icon,
Luciano Ibbaa Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, MI, Italy;b Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, ItalyView further author information
,
Andrea Cortesea Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, MI, Italy;b Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, ItalyView further author information
,
Mario Valentia Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, MI, Italy;b Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, ItalyView further author information
,
Antonio Costanzoa Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, MI, Italy;b Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, ItalyView further author information
&
Alessandra Narcisib Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, ItalyView further author information
 show all
Article: 2200867 | Received 20 Aug 2023, Accepted 04 Mar 2023, Published online: 19 Apr 2023

References

  • Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: clinical implications. Allergy Asthma Proc. 2019;40(2):1–3.
  • Ezzedine K, Shourick J, Merhand S, et al. Impact of atopic dermatitis in adolescents and their parents: a French study. Acta Derm Venereol. 2020;100(17):adv00294. Published 2020 Oct 20.
  • Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409–1431.
  • Gargiulo L, Ibba L, Cortese A, et al. Real-life effectiveness and safety of Upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis: a single-center 16-week study. Dermatol Ther . 2023;13(2):651–660.
  • Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(1):44–56.
  • European Medicines Agency. Dupixent (dupilumab): summary of product characteristics. 2023. [cited 2023 February 15]. Available from: https://www.ema.europa.eu/en/documents/product-information/dupixent-epar-product-information_it.pdf.
  • Blauvelt A, Guttman-Yassky E, Paller AS, et al. Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis: results through week 52 from a phase III open-label extension trial (LIBERTY AD PED-OLE). Am J Clin Dermatol. 2022;23(3):365–383.
  • Pagan AD, David E, Ungar B, et al. Dupilumab improves clinical scores in children and adolescents with moderate to severe atopic dermatitis: a real-world, single-center study. J Allergy Clin Immunol Pract. 2022;10(9):2378–2385.
  • Stingeni L, Bianchi L, Antonelli E, et al. Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: a multicentre Italian real-world experience. J Eur Acad Dermatol Venereol. 2022;36(8):1292–1299.
  • Gargiulo L, Piscazzi F, Ibba L, et al. Dupilumab for the treatment of atopic dermatitis of the elderly: a real-life 52-week experience. J Dermatolog Treat. 2023;34(1):2192840. DOI:10.1080/09546634.2023.2192840
  • Stingeni L, Bianchi L, Antonelli E, et al. A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis. J Eur Acad Dermatol Venereol. 2023;37(3):e384–e388.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.